HIV regulatory proteins: potential targets for therapeutic intervention
- PMID: 1540405
- DOI: 10.1089/aid.1992.8.175
HIV regulatory proteins: potential targets for therapeutic intervention
Abstract
With the incidence of HIV infection on the rise worldwide, it is obvious that new approaches must be taken to halt the spread of disease. Unfortunately, this is no easy task; of all retroviruses studied to date HIV remains the most complex in terms of genomic organization, regulation of gene expression, and replication. However, as the mechanism of action of the unique viral regulatory proteins is deciphered, new windows of opportunity for attacking the virus like cycle are opened. The essential regulatory function served by both Tat and Rev transacting regulatory proteins makes them attractive targets for prophylactic and therapeutic intervention. This review will focus on our current understanding of Tat and Rev function.
Similar articles
-
[RNA ligands for HIV proteins].Tanpakushitsu Kakusan Koso. 1995 Jul;40(10):1430-7. Tanpakushitsu Kakusan Koso. 1995. PMID: 7568944 Review. Japanese. No abstract available.
-
Merged screening for human immunodeficiency virus Tat and Rev inhibitors.J Biomol Screen. 2001 Jun;6(3):179-87. doi: 10.1177/108705710100600308. J Biomol Screen. 2001. PMID: 11689114
-
HIV-1 regulatory proteins: targets for novel drug development.Expert Opin Investig Drugs. 2002 Aug;11(8):1099-115. doi: 10.1517/13543784.11.8.1099. Expert Opin Investig Drugs. 2002. PMID: 12150704 Review.
-
Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.Hum Gene Ther. 2000 Apr 10;11(6):807-15. doi: 10.1089/10430340050015428. Hum Gene Ther. 2000. PMID: 10779158
-
The HIV-1 Tat transactivator protein: a therapeutic target?IUBMB Life. 2003 Dec;55(12):669-80. doi: 10.1080/15216540310001643440. IUBMB Life. 2003. PMID: 14769003 Review.
Cited by
-
Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.J Virol. 1997 May;71(5):4071-8. doi: 10.1128/JVI.71.5.4071-4078.1997. J Virol. 1997. PMID: 9094685 Free PMC article.
-
Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).Drugs. 1993 May;45(5):637-53. doi: 10.2165/00003495-199345050-00002. Drugs. 1993. PMID: 7686460 Review.
-
Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2.J Virol. 2004 Oct;78(20):11303-12. doi: 10.1128/JVI.78.20.11303-11312.2004. J Virol. 2004. PMID: 15452250 Free PMC article.
-
Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.Clin Exp Immunol. 1994 Jul;97(1):61-7. doi: 10.1111/j.1365-2249.1994.tb06580.x. Clin Exp Immunol. 1994. PMID: 8033422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical